# Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract

> **NCT00619827** · PHASE1 · COMPLETED · sponsor: **Stallergenes Greer** · enrollment: 89 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** 300 IR grass pollen allergen extract tablet
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT00619827
- **Lead sponsor:** Stallergenes Greer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2016-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00619827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00619827, "Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00619827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*